Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

27 sept. 2021 06h00 HE | Source: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentations at Society for Melanoma Research (SMR) 2021 Congress

KNOXVILLE, TN, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from historical clinical trials and expanded access studies of investigational cancer...
18 oct. 2017 09h38 HE | Source: Provectus Biopharmaceuticals Inc.

PROVECTUS ANNOUNCES PRELIMINARY RESULTS FROM PHASE 1B TRIAL OF INTRALESIONAL PV-10 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) FOR THE TREATMENT OF STAGE IV MELANOMA

– Adverse events consistent with established patterns for each drug; no unexpected toxicities observed – 50% overall objective response rate; 10% complete response; highest responses observed in...